$7.10
1.25% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US6024961012
Symbol
MDXG

MiMedx Group, Inc. Stock price

$7.10
-0.05 0.70% 1M
-1.20 14.46% 6M
-2.52 26.20% YTD
+0.72 11.29% 1Y
+3.67 107.00% 3Y
+0.50 7.58% 5Y
-2.57 26.58% 10Y
+7.00 7,000.00% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.09 1.25%
ISIN
US6024961012
Symbol
MDXG
Industry

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$963.4m
Net debt
positive
Cash
$118.9m
Shares outstanding
147.9m
Valuation (TTM | estimate)
P/E
34.2 | 21.7
P/S
2.9 | 2.7
EV/Sales
2.7 | 2.5
EV/FCF
16.8
P/B
4.9
Financial Health
Equity Ratio
73.2%
Return on Equity
22.0%
ROCE
18.2%
ROIC
19.8%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$363.8m | $393.1m
EBITDA
$44.5m | $83.5m
EBIT
$43.9m | $50.8m
Net Income
$32.2m | $49.0m
Free Cash Flow
$57.4m
Growth (TTM | estimate)
Revenue
6.9% | 12.7%
EBITDA
-29.4% | 59.8%
EBIT
-29.4% | 0.3%
Net Income
-60.1% | 15.6%
Free Cash Flow
19.2%
Margin (TTM | estimate)
Gross
81.5%
EBITDA
12.2% | 21.2%
EBIT
12.1%
Net
8.8% | 12.5%
Free Cash Flow
15.8%
More
EPS
$0.2
FCF per Share
$0.4
Short interest
4.3%
Employees
837
Rev per Employee
$420.0k
Show more

Is MiMedx Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

MiMedx Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a MiMedx Group, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a MiMedx Group, Inc. forecast:

Buy
91%
Hold
9%

Financial data from MiMedx Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
364 364
7% 7%
100%
- Direct Costs 67 67
19% 19%
19%
296 296
4% 4%
81%
- Selling and Administrative Expenses 239 239
10% 10%
66%
- Research and Development Expense 13 13
45% 45%
4%
45 45
29% 29%
12%
- Depreciation and Amortization 0.58 0.58
24% 24%
0%
EBIT (Operating Income) EBIT 44 44
29% 29%
12%
Net Profit 32 32
60% 60%
9%

In millions USD.

Don't miss a Thing! We will send you all news about MiMedx Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MiMedx Group, Inc. Stock News

Neutral
GlobeNewsWire
about 13 hours ago
To Present Six Posters Featuring the Company's Latest Product Innovations To Present Six Posters Featuring the Company's Latest Product Innovations
Neutral
GlobeNewsWire
8 days ago
MARIETTA, Ga., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
Neutral
Seeking Alpha
about one month ago
MiMedx Group, Inc. (NASDAQ:MDXG ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Douglas C. Rice - Chief Financial Officer Joseph H.
More MiMedx Group, Inc. News

Company Profile

MiMedx Group, Inc. is an advanced wound care and an emerging therapeutic biologics company. It engages in developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx Group was founded on July 30, 1985 and is headquartered in Marietta, GA.

Head office United States
CEO Joe Capper
Employees 837
Founded 1985
Website mimedx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today